Skip to main content

Table 1 Pain and sleep responses at different response levels and doses of pregabalin

From: Pregabalin in fibromyalgia - responder analysis from individual patient data

  

Percent with treatment/placebo

NNT (95% CI)

Outcome

Level

Placebo

300 mg

450 mg

600 mg

300 mg

450 mg

600 mg

Pain: change from baseline

≥ 0%

60

65

68

60

not calculated

13 (8.0 to 41)

not calculated

6 weeks

≥ 15%

44

52

56

52

13 (7.8 to 43)

8.4 (5.8 to 15)

14 (7.6 to 67)

 

≥ 30%

28

36

39

39

10 (6.9 to 21)

8.0 (5.7 to 13)

8.5 (5.8 to 16)

 

≥ 50%

14

21

23

26

14 (8.8 to 30)

12 (7.9 to 22)

8.8 (6.2 to 15)

 

≥ 70%

4.1

7.7

9.0

12

30 (17 to 110)

19 (13 to 38)

14 (9.8 to 26)

Pain: change from baseline

≥ 0%

54

55

60

53

not calculated

not calculated

not calculated

12 weeks

≥ 15%

40

45

49

43

not calculated

12 (6.9 to 35)

not calculated

 

≥ 30%

29

33

38

34

not calculated

11 (6.9 to 29)

not calculated

 

≥ 50%

15

19

21

23

22 (11 to 870)

16 (9.3 to 59)

13 (8.1 to 31)

 

≥ 70%

5.9

6.8

8.5

12

not calculated

not calculated

18 (11 to 43)

Sleep: change from baseline

≥ 0%

59

64

68

61

not calculated

11 (7.0 to 23)

not calculated

6 weeks

≥ 15%

45

53

55

51

11 (7.2 to 29)

9.3 (6.3 to 18)

15 (8.0 to 130)

 

≥ 30%

29

39

43

41

9.4 (6.4 to 17)

6.8 (5.1 to 10)

8.2 (5.7 to 15)

 

≥ 50%

13

25

26

26

9.0 (6.6 to 14)

7.8 (5.9 to 12)

7.7 (5.7 to 12)

 

≥ 70%

3.8

11

13

13

14 (10 to 23)

11 (8.6 to 17)

12 (8.8 to 21)

Sleep: change from baseline

≥ 0%

51

54

58

52

not calculated

14 (7.6 to 68)

not calculated

12 weeks

≥ 15%

37

43

49

44

not calculated

8.9 (5.9 to 19)

16 (8.3 to 170)

 

≥ 30%

25

32

40

35

14 (8.1 to 58)

7.0 (5.1 to 11)

10 (6.6 to 22)

 

≥ 50%

14

21

26

26

13 (8.2 to 30)

8.4 (6.0 to 14)

8.4 (6.1 to 14)

 

≥ 70%

5.0

9.3

10

12

24 (14 to 82)

20 (13 to 55)

14 (9.4 to 24)

  1. NNTs were not calculated when statistical significance was not achieved.